We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Advisory Committee Votes Against AZ, BMS Diabetes Drug
Advisory Committee Votes Against AZ, BMS Diabetes Drug
July 22, 2011
An FDA panel voted 9-6 against recommending approval of Bristol-Myers Squibb (BMS) and AstraZeneca’s diabetes drug dapagliflozin, citing cancer risks and a lack of substantial evidence.